Pharmacological considerations for the proper clinical use of aminoglycosides

Drugs

Volumn 71, Issue 17, 2011, Pages 2277-2294

  Pagkalis, Spyridon ^a   Mantadakis, Elpis ^a   Mavros, Michael N ^b   Ammari, Christina ^c   Falagas, Matthew E ^b,d,e  

^a DEMOCRITUS UNIVERSITY OF THRACE MEDICAL SCHOOL   (Greece)

^b ALFA INSTITUTE OF BIOMEDICAL SCIENCES AIBS   (Greece)

^c UNIVERSITY GENERAL HOSPITAL OF ALEXANDROUPOLIS   (Greece)

^d HENRY DUNANT HOSPITAL   (Greece)

^e TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Aminoglycosides; Antibacterial resistance; Bacterial infections; Plazomicin

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; GENTAMICIN; HABEKACIN; NETILMICIN; TICARCILLIN; TOBRAMYCIN;

ACINETOBACTER; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; AREA UNDER THE CURVE; BACTERIAL GROWTH; BACTERICIDAL ACTIVITY; BIOFILM; CLINICAL PRACTICE; CONCENTRATION RESPONSE; CYSTIC FIBROSIS; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG USE; GLOMERULUS FILTRATION RATE; GRAM NEGATIVE INFECTION; HUMAN; LEUKOCYTE; LOADING DRUG DOSE; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; NEPHROTOXICITY; NONHUMAN; OTOTOXICITY; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; REVIEW; SEPSIS; SEPTIC SHOCK; SEPTICEMIA; TREATMENT OUTCOME;

AMINOGLYCOSIDES; ANIMALS; BACTERIAL INFECTIONS; HUMANS;

ACINETOBACTER; BACTERIA (MICROORGANISMS); NEGIBACTERIA; POSIBACTERIA; PSEUDOMONAS AERUGINOSA;

EID: 81155126016     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11597020-000000000-00000     Document Type: Review

References (141)

1. Sato R, Tanigawara Y, Kaku M, et al. Pharmacokinetic pharmacodynamic relationship of arbekacin for treatment of patients infected with methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2006; 50: 3763-9 (Pubitemid 44684891)
2. Mingeot-Leclercq MP, Tulkens PM. Aminoglycosides: nephrotoxicity. Antimicrob Agents Chemother 1999; 43: 1003-12 (Pubitemid 29214718)
3. Guthrie OW. Aminoglycoside induced ototoxicity. Toxicology 2008; 249: 91-6
4. Durante-Mangoni E, Grammatikos A, Utili R, et al. Do we still need the aminoglycosides? Int J Antimicrob Agents 2009; 33: 201-5
5. Falagas ME, Grammatikos AP, Michalopoulos A. Potential of old-generation antibiotics to address current need for new antibiotics. Expert Rev Anti Infect Ther 2008; 6: 593-600
6. Fluit AC, Jones ME, Schmitz FJ, et al. Antimicrobial susceptibility and frequency of occurrence of clinical blood isolates in Europe from the SENTRY antimicrobial surveillance program, 1997 and 1998. Clin Infect Dis 2000; 30: 454-60 (Pubitemid 30205288)
7. Sader HS, Biedenbach DJ, Jones RN. Global patterns of susceptibility for 21 commonly utilized antimicrobial agents tested against 48, 440 Enterobacteriaceae in the SENTRY Antimicrobial Surveillance Program (1997-2001). Diagn Microbiol Infect Dis 2003; 47: 361-4 (Pubitemid 37101170)
8. Gales AC, Jones RN, Turnidge J, et al. Characterization of Pseudomonas aeruginosa isolates: occurrence rates, antimicrobial susceptibility patterns, and molecular typing in the global SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin Infect Dis 2001; 32 Suppl. 2: S146-55 (Pubitemid 32424268)
9. Jones RN, Sader HS, BeachML. Contemporary in vitro spectrum of activity summary for antimicrobial agents tested against 18569 strains non-fermentative Gram-negative bacilli isolated in the SENTRY Antimicrobial Surveillance Program (1997-2001). Int J Antimicrob Agents 2003; 22: 551-6 (Pubitemid 37494988)
10. Layeux B, Taccone FS, Fagnoul D, et al. Amikacin monotherapy for sepsis caused by panresistant Pseudomonas aeruginosa. Antimicrob Agents Chemother 2010; 54: 4939-41
11. Obritsch MD, Fish DN, MacLaren R, et al. National surveillance of antimicrobial resistance in Pseudomonas aeruginosa isolates obtained from intensive care unit patients from 1993 to 2002. Antimicrob Agents Chemother 2004; 48: 4606-10 (Pubitemid 39577660)
12. Matsuhashi Y, Yamamoto H. The enzymatic mechanisms of resistance to aminoglycoside antibiotics in methicillincephem-resistant Staphylococcus aureus. Jpn J Antibiot 1988; 41: 523-9
13. Craig WA, Redington J, Ebert SC. Pharmacodynamics of amikacin in vitro and in mouse thigh and lung infections. J Antimicrob Chemother 1991; 27 Suppl. C: 29-40
14. MacArthur RD, Lolans V, Zar FA, et al. Biphasic, concentration-dependent and rate-limited, concentrationindependent bacterial killing by an aminoglycoside antibiotic. J Infect Dis 1984; 150: 778-9 (Pubitemid 15200090)
15. Tam VH, Kabbara S, Vo G, et al. Comparative pharmacodynamics of gentamicin against Staphylococcus aureus and Pseudomonas aeruginosa. Antimicrob Agents Chemother 2006; 50: 2626-31 (Pubitemid 44198680)
16. Ambrose PG, Bhavnani SM, Rubino CM, et al. Pharmacokinetics- pharmacodynamics of antimicrobial therapy: it's not just for mice anymore. Clin Infect Dis 2007; 44: 79-86 (Pubitemid 44968990)
17. Craig WA, Ebert SC. Killing and regrowth of bacteria in vitro: a review. Scand J Infect Dis Suppl 1990; 74: 63-70
18. Blaser J, Stone BB, Zinner SH. Efficacy of intermittent versus continuous administration of netilmicin in a twocompartment in vitro model. Antimicrob Agents Chemother 1985; 27: 343-9 (Pubitemid 15144697)
19. Blaser J, Stone BB, Groner MC, et al. Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance. Antimicrob Agents Chemother 1987; 31: 1054-60 (Pubitemid 17099578)
20. Tam VH, Nikolaou M. A novel approach to pharmacodynamic assessment of antimicrobial agents: new insights to dosing regimen design. PLoS Comput Biol 2011; 7: e1001-43
21. Tam VH, Schilling AN, Nikolaou M. Modelling time-kill studies to discern the pharmacodynamics of meropenem. J Antimicrob Chemother 2005; 55: 699-706 (Pubitemid 40691849)
22. Tam VH, Ledesma KR, Vo G, et al. Pharmacodynamic modeling of aminoglycosides against Pseudomonas aeruginosa and Acinetobacter baumannii: identifying dosing regimens to suppress resistance development. Antimicrob Agents Chemother 2008; 52: 3987-93
23. Moore RD, Lietman PS, Smith CR. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis 1987; 155: 93-9 (Pubitemid 17225088)
24. Kashuba AD, Nafziger AN, Drusano GL, et al. Optimizing aminoglycoside therapy for nosocomial pneumonia caused by gram-negative bacteria. Antimicrob Agents Chemother 1999; 43: 623-9 (Pubitemid 29109529)
25. Smith PF, Ballow CH, Booker BM, et al. Pharmacokinetics and pharmacodynamics of aztreonam and tobramycin in hospitalized patients. Clin Ther 2001; 23: 1231-44 (Pubitemid 32804116)
26. Zelenitsky SA, Harding GK, Sun S, et al. Treatment and outcome of Pseudomonas aeruginosa bacteraemia: an antibiotic pharmacodynamic analysis. J Antimicrob Chemother 2003; 52: 668-74 (Pubitemid 37258430)
27. Mouton JW, Jacobs N, Tiddens H, et al. Pharmacodynamics of tobramycin in patients with cystic fibrosis. Diagn Microbiol Infect Dis 2005; 52: 123-7 (Pubitemid 40826938)
28. Chuck SK, Raber SR, Rodvold KA, et al. National survey of extended-interval aminoglycoside dosing. Clin Infect Dis 2000; 30: 433-9 (Pubitemid 30205284)
29. Begg EJ, Barclay ML, Duffull SB. A suggested approach to once-daily aminoglycoside dosing. Br J Clin Pharmacol 1995; 39: 605-9
30. European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 1.3, January 5, 2011[online]. Available from URL: http://www.eucast.org/fileadmin/src/media/ PDFs/EUCAST-files/Disk-test-documents/EUCAST-breakpoints-v1.3-pdf.pdf [Accessed 2011 Oct 12]
31. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing: 21st informational supplement [CLSI document M100-S21]. Wayne (PA): CL SI, 2011 Jan
32. Frei CR, Wiederhold NP, Burgess DS. Antimicrobial breakpoints for gram-negative aerobic bacteria based on pharmacokinetic-pharmacodynamic models with Monte Carlo simulation. J Antimicrob Chemother 2008; 61: 621-8 (Pubitemid 351321137)
33. Bhavnani SM, Ambrose PG, Jones RN, et al. To split, or not to split aMIC distribution, that is the question: setting susceptibility break-points [abstract no. D-222]. Abstracts of the Forty-seventh Interscience Conference on Antimicrobial Agents and Chemotherapy; 2007 Sep 17-20; Chicago (IL). Washington, DC: American Society for Microbiology, 2007: 153
34. Marik PE. Aminoglycoside volume of distribution and illness severity in critically ill septic patients. Anaesth Intensive Care 1993; 21: 172-3 (Pubitemid 23132762)
35. Dorman T, Swoboda S, Zarfeshenfard F, et al. Impact of altered aminoglycoside volume of distribution on the adequacy of a three milligram per kilogram loading dose. Critical Care Research Group. Surgery 1998; 124: 73-8 (Pubitemid 28354688)
36. Botha FJ, van der Bijl P, Seifart HI, et al. Fluctuation of the volume of distribution of amikacin and its effect on oncedaily dosage and clearance in a seriously ill patient. Intensive Care Med 1996; 22: 443-6 (Pubitemid 26174317)
37. Ronchera-Oms CL, Tormo C, Ordovas JP, et al. Expanded gentamicin volume of distribution in critically ill adult patients receiving total parenteral nutrition. J Clin Pharm Ther 1995; 20: 253-8
38. Etzel JV, Nafziger AN, Bertino Jr JS. Variation in the pharmacokinetics of gentamicin and tobramycin in patients with pleural effusions and hypoalbuminemia. Antimicrob Agents Chemother 1992; 36: 679-81
39. Sampliner R, Perrier D, Powell R, et al. Influence of ascites on tobramycin pharmacokinetics. J Clin Pharmacol 1984; 24: 43-6 (Pubitemid 14154713)
40. Worman LW. The role of fluid sequestration in the pathogenesis of mediastinitis. Am J Surg 1966; 111: 813-8
41. Romano S, Fdez de Gatta MM, Calvo MV, et al. Population pharmacokinetics of amikacin in patients with haematological malignancies. J Antimicrob Chemother 1999; 44: 235-42 (Pubitemid 29389287)
42. Dudley MN, Ambrose PG. Pharmacodynamics in the study of drug resistance and establishing in vitro susceptibility breakpoints: ready for prime time. Curr Opin Microbiol 2000; 3: 515-21
43. Nicolau DP, Freeman CD, Belliveau PP, et al. Experience with a once-daily aminoglycoside program administered to 2, 184 adult patients. Antimicrob Agents Chemother 1995; 39: 650-5
44. Rea RS, Capitano B, Bies R, et al. Suboptimal aminoglycoside dosing in critically ill patients. Ther Drug Monit 2008; 30: 674-81
45. Taccone FS, Laterre PF, Spapen H, et al. Revisiting the loading dose of amikacin for patients with severe sepsis and septic shock. Crit Care 2010; 14 (2): R53
46. Drusano GL, Ambrose PG, Bhavnani SM, et al. Back to the future: using aminoglycosides again and how to dose them optimally. Clin Infect Dis 2007; 45: 753-60 (Pubitemid 47378891)
47. Trotman RL, Williamson JC, Shoemaker DM, et al. Antibiotic dosing in critically ill adult patients receiving continuous renal replacement therapy. Clin Infect Dis 2005; 41: 1159-66 (Pubitemid 41429480)
48. Begg EJ, Vella-Brincat JW, Robertshawe B, et al. Eight years' experience of an extended-interval dosing protocol for gentamicin in neonates. J Antimicrob Chemother 2009; 63: 1043-9
49. InparajahM, Wong C, Sibbald C, et al. Once-daily gentamicin dosing in children with febrile neutropenia resulting from antineoplastic therapy. Pharmacotherapy 2010; 30: 43-51
50. Matthews I, Kirkpatrick C, Holford N. Quantitative justification for target concentration intervention: parameter variability and predictive performance using population pharmacokinetic models for aminoglycosides. Br J Clin Pharmacol 2004; 58: 8-19 (Pubitemid 38901461)
51. McNamara DR, Nafziger AN, Menhinick AM, et al. A dose-ranging study of gentamicin pharmacokinetics: implications for extended interval aminoglycoside therapy. J Clin Pharmacol 2001; 41: 374-7 (Pubitemid 32274980)
52. Van Eldere J. Multicentre surveillance of Pseudomonas aeruginosa susceptibility patterns in nosocomial infections. J Antimicrob Chemother 2003; 51: 347-52 (Pubitemid 36231155)
53. Daikos GL, Lolans VT, Jackson GG. First-exposure adaptive resistance to aminoglycoside antibiotics in vivo with meaning for optimal clinical use. Antimicrob Agents Chemother 1991; 35: 117-23
54. Daikos GL, Jackson GG, Lolans VT, et al. Adaptive resistance to aminoglycoside antibiotics from first-exposure down-regulation. J Infect Dis 1990; 162: 414-20 (Pubitemid 20239957)
55. Barclay ML, Begg EJ, Chambers ST. Adaptive resistance following single doses of gentamicin in a dynamic in vitro model. Antimicrob Agents Chemother 1992; 36: 1951-7
56. Karlowsky JA, Saunders MH, Harding GA, et al. In vitro characterization of aminoglycoside adaptive resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother 1996; 40: 1387-93 (Pubitemid 26169047)
57. Hocquet D, Vogne C, El Garch F, et al. MexXY-OprM efflux pump is necessary for a adaptive resistance of Pseudomonas aeruginosa to aminoglycosides. Antimicrob Agents Chemother 2003; 47: 1371-5 (Pubitemid 36368599)
58. Ransil BJ, Greenblatt DJ, Koch-Weser J. Evidence for systematic temporal variation in 24-hour urinary creatinine excretion. J Clin Pharmacol 1977; 17: 108-19 (Pubitemid 8035570)
59. Elting L, Bodey GP, Rosenbaum B, et al. Circadian variation in serum amikacin levels. J Clin Pharmacol 1990; 30: 798-801 (Pubitemid 20334339)
60. Lucht F, Tigaud S, Esposito G, et al. Chronokinetic study of netilmicin in man. Eur J Clin Pharmacol 1990; 39: 199-201 (Pubitemid 20250001)
61. Dickson CJ, Schwartzman MS, Bertino Jr JS. Factors affecting aminoglycoside disposition: effects of circadian rhythm and dietary protein intake on gentamicin pharmacokinetics. Clin Pharmacol Ther 1986; 39: 325-8 (Pubitemid 16113642)
62. Bosch JP, Saccaggi A, Lauer A, et al. Renal functional reserve in humans: effect of protein intake on glomerular filtration rate. Am J Med 1983; 75: 943-50 (Pubitemid 14204584)
63. Brenner BM, Meyer TW, Hostetter TH. Dietary protein intake and the progressive nature of kidney disease: the role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal disease. N Engl J Med 1982; 307: 652-9 (Pubitemid 12049914)
64. Prins JM, Weverling GJ, van Ketel RJ, et al. Circadian variations in serum levels and the renal toxicity of aminoglycosides in patients. Clin Pharmacol Ther 1997; 62: 106-11 (Pubitemid 27327104)
65. Nakano S, Song J, Ogawa N. Chronopharmacokinetics of gentamicin: comparison between man and mice. Ann Rev Chronopharmacol 1990; 7: 277-80 (Pubitemid 20363793)
66. Rybak MJ, Abate BJ, Kang SL, et al. Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity. Antimicrob Agents Chemother 1999; 43: 1549-55 (Pubitemid 29331226)
67. Murry KR, McKinnon PS, Mitrzyk B, et al. Pharmacodynamic characterization of nephrotoxicity associated with once-daily aminoglycoside. Pharmacotherapy 1999; 19: 1252-60
68. de Hoog M, Schoemaker RC, Mouton JW, et al. Tobramycin population pharmacokinetics in neonates. Clin Pharmacol Ther 1997; 62: 392-9 (Pubitemid 27475223)
69. Nielsen EI, Sandstrom M, Honore PH, et al. Developmental pharmacokinetics of gentamicin in preterm and term neonates: population modelling of a prospective study. Clin Pharmacokinet 2009; 48: 253-63
70. Olsen NV, Lund J, Jensen PF, et al. Dopamine, dobutamine, and dopexamine: a comparison of renal effects in unanesthetized human volunteers. Anesthesiology 1993; 79: 685-94 (Pubitemid 23296698)
71. Tang GJ, Tang JJ, Lin BS, et al. Factors affecting gentamicin pharmacokinetics in septic patients. Acta Anaesthesiol Scand 1999; 43: 726-30 (Pubitemid 29362047)
72. de Groot R, Smith AL. Antibiotic pharmacokinetics in cystic fibrosis: differences and clinical significance. Clin Pharmacokinet 1987; 13: 228-53 (Pubitemid 17165720)
73. Fuster-Lluch O, Geronimo-Pardo M, Peyro-Garcia R, et al. Glomerular hyperfiltration and albuminuria in critically ill patients. Anaesth Intensive Care 2008; 36: 674-80
74. Streetman DS, Nafziger AN, Destache CJ, et al. Individualized pharmacokinetic monitoring results in less aminoglycoside-associated nephrotoxicity and fewer associated costs. Pharmacotherapy 2001; 21: 443-51 (Pubitemid 32275273)
75. Conil JM, Georges B, Ruiz S, et al. Tobramycin disposition in ICU patients receiving a once daily regimen: population approach and dosage simulations. Br J Clin Pharmacol 2011; 71: 61-71
76. Craig WA. Post-antibiotic effects in experimental infection models: relationship to in vitro phenomena and to treatment of infections in man. J Antimicrob Chemother 1993; 31 Suppl. D: 149-58 (Pubitemid 23193761)
77. McDonald PJ, Craig WA, Kunin CM. Persistent effect of antibiotics on Staphylococcus aureus after exposure for limited periods of time. J Infect Dis 1977; 135: 217-23 (Pubitemid 8049531)
78. Vogelman BS, Craig WA. Postantibiotic effects. J Antimicrob Chemother 1985; 15 Suppl. A: 37-46 (Pubitemid 15079546)
79. den Hollander JG, Fuursted K, Verbrugh HA, et al. Duration and clinical relevance of postantibiotic effect in relation to the dosing interval. Antimicrob Agents Chemother 1998; 42: 749-54 (Pubitemid 28216348)
80. Isaksson B, Nilsson L, Maller R, et al. Postantibiotic effect of aminoglycosides on gram-negative bacteria evaluated by a new method. J Antimicrob Chemother 1988; 22: 23-33
81. Karlowsky JA, Zhanel GG, Davidson RJ, et al. Postantibiotic effect in Pseudomonas aeruginosa following single and multiple aminoglycoside exposures in vitro. J Antimicrob Chemother 1994; 33: 937-47 (Pubitemid 24170893)
82. Bundtzen RW, Gerber AU, Cohn DL, et al. Postantibiotic suppression of bacterial growth. Rev Infect Dis 1981; 3: 28-37
83. Bermudez LE, Wu M, Young LS, et al. Postantibiotic effect of amikacin and rifapentine against Mycobacterium avium complex. J Infect Dis 1992; 166: 923-6
84. den Hollander JG, Mouton JW, van Goor MP, et al. Alteration of postantibiotic effect during one dosing interval of tobramycin, simulated in an in vitro pharmacokinetic model. Antimicrob Agents Chemother 1996; 40: 784-6 (Pubitemid 26071551)
85. Fantin B, Ebert S, Leggett J, et al. Factors affecting duration of in-vivo postantibiotic effect for aminoglycosides against gram-negative bacilli. J Antimicrob Chemother 1991; 27: 829-36
86. Mouton JW, Vinks AA. Pharmacokinetic/pharmacodynamic modelling of antibacterials in vitro and in vivo using bacterial growth and kill kinetics: the minimum inhibitory concentration versus stationary concentration. Clin Pharmacokinet 2005; 44: 201-10 (Pubitemid 40188941)
87. Zhanel GG, Karlowsky JA, Hoban DJ, et al. Antimicrobial activity of subinhibitory concentrations of aminoglycosides against Pseudomonas aeruginosa as determined by the killing-curve method and the postantibiotic effect. Chemotherapy 1991; 37: 114-21
88. Odenholt-Tornqvist I, Lowdin E, Cars O. Pharmacodynamic effects of subinhibitory concentrations of betalactam antibiotics in vitro. Antimicrob Agents Chemother 1991; 35: 1834-9
89. Odenholt I. Pharmacodynamic effects of subinhibitory antibiotic concentrations. Int J Antimicrob Agents 2001; 17: 1-8 (Pubitemid 32008653)
90. Odenholt-Tornqvist I, Lowdin E, Cars O. Postantibiotic sub-MIC effects of vancomycin, roxithromycin, sparfloxacin, and amikacin. Antimicrob Agents Chemother 1992; 36: 1852-8
91. McDonald PJ, Wetherall BL, Pruul H. Postantibiotic leukocyte enhancement: increased susceptibility of bacteria pretreated with antibiotics to activity of leukocytes. Rev Infect Dis 1981; 3 (1): 38-44
92. Novelli A, Mazzei T, Fallani S, et al. In vitro postantibiotic effect and postantibiotic leukocyte enhancement of tobramycin. J Chemother 1995; 7: 355-62
93. Schlaeffer F, Blaser J, Laxon J, et al. Enhancement of leucocyte killing of resistant bacteria selected during exposure to aminoglycosides or quinolones. J Antimicrob Chemother 1990; 25: 941-8 (Pubitemid 20212438)
94. Gerber AU, Vastola AP, Brandel J, et al. Selection of aminoglycoside-resistant variants of Pseudomonas aeruginosa in an in vivo model. J Infect Dis 1982; 146: 691-7 (Pubitemid 13250823)
95. Kapusnik JE, Hackbarth CJ, Chambers HF, et al. Single, large, daily dosing versus intermittent dosing of tobramycin for treating experimental pseudomonas pneumonia. J Infect Dis 1988; 158: 7-12
96. Iida K, Koike M. Cell wall alterations of gram-negative bacteria by aminoglycoside antibiotics. Antimicrob Agents Chemother 1974; 5: 95-7
97. Raponi G, Keller N, Overbeek BP, et al. Enhanced phagocytosis of encapsulated Escherichia coli strains after exposure to sub-MICs of antibiotics is correlated to changes of the bacterial cell surface. Antimicrob Agents Chemother 1990; 34: 332-6 (Pubitemid 20046890)
98. Raponi G, Vreede RW, Rozenberg-Arska M, et al. The influence of subminimal inhibitory concentrations of netilmicin and ceftriaxone on the interaction of Escherichia coli with host defences. J Antimicrob Chemother 1989; 23: 565-76 (Pubitemid 19119068)
99. Sadovskaya I, Vinogradov E, Li J, et al. High-level antibiotic resistance in Pseudomonas aeruginosa biofilm: the ndvB gene is involved in the production of highly glycerolphosphorylated beta-(1-3)-glucans, which bind aminoglycosides. Glycobiology 2010; 20: 895-904
100. Buchholz F, Wolf A, Lerchner J, et al. Chip calorimetry for fast and reliable evaluation of bactericidal and bacteriostatic treatments of biofilms. Antimicrob Agents Chemother 2010; 54: 312-9
101. Chambless JD, Hunt SM, Stewart PS. A three-dimensional computer model of four hypothetical mechanisms protecting biofilms from antimicrobials. Appl Environ Microbiol 2006; 72: 2005-13
102. Barclay ML, Begg EJ, Chambers ST, et al.Adaptive resistance to tobramycin in Pseudomonas aeruginosa lung infection in cystic fibrosis. J Antimicrob Chemother 1996; 37: 1155-64 (Pubitemid 26258061)
103. Kirketerp-Moller K, Jensen PO, Fazli M, et al. Distribution, organization, and ecology of bacteria in chronic wounds. J Clin Microbiol 2008; 46: 2717-22
104. Lomovskaya O, Bostian KA. Practical applications and feasibility of efflux pump inhibitors in the clinic: a vision for applied use. Biochem Pharmacol 2006; 71: 910-8
105. LewisK. Persister cells.AnnuRevMicrobiol 2010; 64: 357-72
106. Langton Hewer SC, Smyth AR. Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis. Cochrane Database Syst Rev 2009 Oct 7; (4): CD004197
107. Ratjen F, Munck A, Kho P, et al., ELITE Study Group. Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: the ELITE trial. Thorax 2010; 65: 286-91
108. Contopoulos-Ioannidis DG, Giotis ND, Baliatsa DV, et al. Extended-interval aminoglycoside administration for children: a meta-analysis. Pediatrics 2004; 114: e111-8
109. Hatala R, Dinh T, Cook DJ. Once-daily aminoglycoside dosing in immunocompetent adults: a meta-analysis. Ann Intern Med 1996; 124: 717-25
110. Mavros MN, Polyzos KA, Rafailidis PI, et al. Once versus multiple daily dosing of aminoglycosides for patients with febrile neutropenia: a systematic review and metaanalysis. J Antimicrob Chemother 2011; 66: 251-9
111. Smyth AR, Bhatt J. Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis. Cochrane Database Syst Rev 2010 Jan 20; (1): CD002009
112. Teigen MM, Duffull S, Dang L, et al. Dosing of gentamicin in patients with end-stage renal disease receiving hemodialysis. J Clin Pharmacol 2006; 46: 1259-67 (Pubitemid 44564355)
113. Mitchell G, Brouillette E, Seguin DL, et al. A role for sigma factor B in the emergence of Staphylococcus aureus smallcolony variants and elevated biofilm production resulting from an exposure to aminoglycosides. Microb Pathog 2010; 48: 18-27
114. Hoffman LR, D'Argenio DA, MacCoss MJ, et al. Aminoglycoside antibiotics induce bacterial biofilm formation. Nature 2005; 436: 1171-5 (Pubitemid 41232296)
115. Singh R, Ray P, Das A, et al. Role of persisters and smallcolony variants in antibiotic resistance of planktonic and biofilm-associated Staphylococcus aureus: an in vitro study. J Med Microbiol 2009; 58: 1067-73
116. ter Braak EW, de Vries PJ, Bouter KP, et al. Once-daily dosing regimen for aminoglycoside plus beta-lactam combination therapy of serious bacterial infections: comparative trial with netilmicin plus ceftriaxone. Am J Med 1990; 89: 58-66 (Pubitemid 20196715)
117. Kim MJ, Bertino Jr JS, Erb TA, et al. Application of Bayes theorem to aminoglycoside-associated nephrotoxicity: comparison of extended-interval dosing, individualized pharmacokinetic monitoring, and multiple-daily dosing. J Clin Pharmacol 2004; 44: 696-707 (Pubitemid 38765931)
118. Bertino Jr JS, Booker LA, Franck PA, et al. Incidence of and significant risk factors for aminoglycoside-associated nephrotoxicity in patients dosed by using individualized pharmacokinetic monitoring. J Infect Dis 1993; 167: 173-9 (Pubitemid 23002853)
119. Silverblatt FJ, Kuehn C. Autoradiography of gentamicin uptake by the rat proximal tubule cell. Kidney Int 1979; 15: 335-45 (Pubitemid 10219854)
120. Schmitz C, Hilpert J, Jacobsen C, et al. Megalin deficiency offers protection from renal aminoglycoside accumulation. J Biol Chem 2002; 277: 618-22 (Pubitemid 34952099)
121. Myrdal SE, Johnson KC, Steyger PS. Cytoplasmic and intra-nuclear binding of gentamicin does not require endocytosis. Hear Res 2005; 204: 156-69 (Pubitemid 40733213)
122. Kaloyanides GJ. Drug-phospholipid interactions: role in aminoglycoside nephrotoxicity. Ren Fail 1992; 14: 351-7
123. Bennett WM, Mela-Riker LM, Houghton DC, et al. Microsomal protein synthesis inhibition: an early manifestation of gentamicin nephrotoxicity. Am J Physiol 1988; 255: F265-9
124. Mela-Riker LM, Widener LL, Houghton DC, et al. Renal mitochondrial integrity during continuous gentamicin treatment. Biochem Pharmacol 1986; 35: 979-84 (Pubitemid 16019862)
125. Sandoval RM, Molitoris BA. Gentamicin traffics retrograde through the secretory pathway and is released in the cytosol via the endoplasmic reticulum. Am J Physiol Renal Physiol 2004; 286: F617-24 (Pubitemid 38365078)
126. Rougier F, Ducher M, Maurin M, et al. Aminoglycoside dosages and nephrotoxicity: quantitative relationships. Clin Pharmacokinet. 2003; 42: 493-500 (Pubitemid 36649042)
127. Hashino E, Shero M. Endocytosis of aminoglycoside antibiotics in sensory hair cells. Brain Res 1995; 704: 135-40
128. Marcotti W, van Netten SM, Kros CJ. The aminoglycoside antibiotic dihydrostreptomycin rapidly enters mouse outer hair cells through the mechano-electrical transducer channels. J Physiol 2005; 567: 505-21 (Pubitemid 41301048)
129. Wang Q, Kachelmeier A, Steyger PS. Competitive antagonism of fluorescent gentamicin uptake in the cochlea. Hear Res 2010; 268: 250-9
130. Aran JM, Dulon D, Hiel H, et al. Ototoxicity of aminosides: recent results on uptake and clearance of gentamycin by sensory cells of the cochlea. Rev Laryngol Otol Rhinol (Bord) 1993; 114: 125-8
131. Li H, Steyger PS. Synergistic ototoxicity due to noise exposure and aminoglycoside antibiotics. Noise Health 2009; 11: 26-32
132. Owens KN, Coffin AB, Hong LS, et al. Response of mechanosensory hair cells of the zebrafish lateral line to aminoglycosides reveals distinct cell death pathways. Hear Res 2009; 253: 32-41
133. Westbrock-Wadman S, Sherman DR, Hickey MJ, et al. Characterization of a Pseudomonas aeruginosa efflux pump contributing to aminoglycoside impermeability. Antimicrob Agents Chemother 1999; 43: 2975-83
134. Cottarel G, Wierzbowski J. Combination drugs, an emerging option for antibacterial therapy. Trends Biotechnol 2007; 25: 547-55 (Pubitemid 350138177)
135. Daigle DM, McKay GA, Wright GD. Inhibition of aminoglycoside antibiotic resistance enzymes by protein kinase inhibitors. J Biol Chem 1997; 272: 24755-8 (Pubitemid 27415642)
136. Fajardo A, Martinez-Martin N, Mercadillo M, et al. The neglected intrinsic resistome of bacterial pathogens. PLoS One 2008; 3: e1619
137. Lee S, Hinz A, Bauerle E, et al. Targeting a bacterial stress response to enhance antibiotic action. Proc Natl Acad Sci USA 2009; 106: 14570-5
138. Aggen JB, Armstrong ES, Goldblum AA, et al. Synthesis and spectrum of the neoglycoside ACHN-490. Antimicrob Agents Chemother 2010; 54: 4636-42
139. Halwani M, Hebert S, Suntres ZE, et al. Bismuth-thiol incorporation enhances biological activities of liposomal tobramycin against bacterial biofilm and quorum sensing molecules production by Pseudomonas aeruginosa. Int J Pharm 2009; 373: 141-6
140. Hui T, Yongqing X, Tiane Z, et al. Treatment of osteomyelitis by liposomal gentamicin-impregnated calcium sulfate. Arch Orthop Trauma Surg 2009; 129: 1301-8
141. Rukholm G, Mugabe C, Azghani AO, et al. Antibacterial activity of liposomal gentamicin against Pseudomonas aeruginosa: a time-kill study. Int J Antimicrob Agents 2006; 27: 247-52 (Pubitemid 43246956)